Lymphatic metastasis is related to the epithelial-mesenchymal transition and expressions of VEGF, MMP-9, and COX-2 in breast cancer

Lymphatic metastasis is related to the epithelial-mesenchymal transition and expressions of VEGF, MMP-9, and COX-2 in breast cancer

Abstract

The invasion and metastasis of breast cancer are supposed to involve several stages in which epithelial-mesenchymal transition (EMT) is regarded as the mechanistic basis for the behavior of cancer cells. A series of factors related to EMT are apparently involved in such process. The current study aimed to investigate the contributions of EMT and related factors in lymph node metastasis of breast cancer. The expressions of E-cadherin (E-Cad), N-cadherin (N-Cad), vascular endothelial cell growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), cyclooxygenase-2 (COX-2), and CD34 were examined in 74 cases of breast cancer, including 39 cases with lymph node metastasis and 35 cases without lymph node metastasis by immunohistochemistry. Multivariable Cox proportional hazards model was used to analyze the patients’ prognosis. The expressions of N-Cad, VEGF, MMP-9, and COX-2 in cases with lymph node metastasis were significantly higher than those without lymph node metastasis (P<0.05), while the E-Cad level was inversely related to status of lymph node metastasis (P<0.05). The metastasis rate of lymph node in the cases with EMT (lower E-Cad expression and higher N-Cad expression) was 78.3%, while that without EMT (higher E-Cad expression and lower N-Cad expression) was 11.1%. There was a statistical difference in the expression of COX-2 protein between histological grade I and grade II or III, respectively (P<0.05). In the cases with higher grade, the expression of E-Cad was decreased, while that of N-Cad was increased. Higher microvascular density (MVD) was also found to be significantly associated with lymphatic metastasis (P<0.05), and the cases with higher MVD had shorter survival time. This study indicates that EMT and expressions of VEGF, MMP-9 and COX-2, and MVD value are strongly correlated with lymph node metastasis in breast cancer.

Keywords

epithelial-mesenchymal transition / vascular endothelial cell growth factor / matrix metalloproteinase-9 / cyclooxygenase-2 / higher microvascular density / breast cancer

参考文献

[1] LiG,YangT,YanJ.Cyclooxygenase-2 increased the angiogenic and metastatic potential of tumor cells.Biochem Biophys Res Commun,2002,299(5):886-890

[2] ThieryJ P,SleemanJ P.Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol, 2006, 7(2):131-142

[3] MaedaM,JohnsonK R,WheelockM J.Cadherin switching: essential for behavioral but not morphological changes during an epithelium-to-mesenchyme transition.J Cell Sci,2005, 118(Pt5): 873-887

[4] LouY,PreobrazhenskaO,auf dem KellerU,SutcliffeM,BarclayL,McDonaldP C, RoskelleyC,OverallC M,DedharS.Epithelial-mesenchymal transition (EMT) is not sufficient for spontaneous murine breast cancer metastasis.Dev Dyn,2008,237(10):2755-2768

[5] NeveR M,ChinK,FridlyandJ,YehJ,BaehnerF L,FevrT,ClarkL,BayaniN,CoppeJ P,TongF,SpeedT,SpellmanP T,DeVriesS,LapukA,WangN J,KuoW L,StilwellJ L,PinkelD,AlbertsonD G,WaldmanF M,McCormickF,DicksonR B,JohnsonM D,LippmanM,EthierS,GazdarA,GrayJ W.A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.Cancer Cell,2006,10(6): 515-527

[6] HazanR B,KangL,WhooleyB P,BorgenP I.N-cadherin promotes adhesion between invasive breast cancer cells and the stroma.Cell Adhes Commun,1997,4(6):399-411

[7] SabbahM,EmamiS,RedeuilhG,JulienS,PrevostG,ZimberA,OuelaaR,BrackeM,De WeverO,GespachC.Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers.Drug Resist Updat, 2008,11(4,5): 123-151

[8] SaadR S,KordunskyL,LiuY L,DenningK L,KandilH A,SilvermanJ F.Lymphatic microvessel density as prognostic marker in colorectal cancer.Mod Pathol,2006,19(10): 1317-1323

[9] ShibataM A,MorimotoJ,ShibataE,OtsukiY.Combination therapy with short interfering RNA vectors against VEGF-C and VEGF-A suppresses lymph node and lung metastasis in a mouse immunocompetent mammary cancer model.Cancer Gene Ther,2008,15(12):776-786

[10] HirakawaS,BrownL F,KodamaS,PaavonenK,AlitaloK,DetmarM.VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites.Blood, 2007,109(3): 1010-1017

[11] KaplanR N,RibaR D,ZacharoulisS,BramleyA H,VincentL,CostaC,MacDonaldD D,JinD K,ShidoK,KernsS A,ZhuZ,HicklinD,WuY,PortJ L,AltorkiN,PortE R,RuggeroD,ShmelkovS V,JensenK K,RafiiS,LydenD.VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche.Nature,2005,438(7069):820-827

[12] HiratsukaS,WatanabeA,AburataniH,MaruY.Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis.Nat Cell Biol, 2006,8(12):1369-1375

[13] QuarantaM,DanieleA,CovielloM,VenneriM T,AbbateI,CaringellaM E,Di TardoS,Divella,R,TrerotoliP,Di GennaroM,SchittulliF,FransveaE,GiannelliG.MMP-2, MMP-9, VEGF and CA 15.3 in breast cancer.Anticancer Res,2007,27(5B):3593-3600

[14] KawataN,NaganeY,HirakataH,IchinoseT,OkadaY,YamaguchiK,TakahashiS. Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma.Urology,2007, 69(6):1049-1053

[15] ZhangX,YamashitaM,UetsukiH,KakehiY.Angiogenesis in renal cell carcinoma: Evaluation of microvessel density, vascular endothelial growth factor and matrix metalloproteinases.Int J Urol, 2002,9(9):509-514

[16] PrzybyloJ A,RadiskyD C.Matrix metalloproteinase-induced epithelial-mesenchymal transition: tumor progression at Snail's pace.Int J Biochem Cell Biol,2007,39(6):1082-1088

[17] Cowden DahlK D,SymowiczJ,NingY,GutierrezE,FishmanD A,AdleyB P,StackM S,HudsonL G.Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent e-cadherin loss in ovarian carcinoma cells.Cancer Res,2008,68(12):4606-4613

[18] NozoeT,EzakiT,KabashimaA.BabaH,Maehara,Y.Significance of immunohistochemical expression of cyclooxygenase-2 in squamous cell carcinoma of the esophagus.Am J Surg,2005, 189(1):110-115

[19] ReddyB S,RaoC V.Colon cancer: a role for cyclo-oxygenase-2-specific nonsteroidal anti-inflammatory drugs.Drugs Aging,2000,16(5): 329-334

[20] SaukkonenK,RintahakaJ,SivulaA,BuskensC J,van ReesB P,RioM C,HaglundC,van LanschotJ J,OfferhausG J,RistimakiA.Cyclooxygenase-2 and gastric carcinogenesis.Apmis, 2003,111(10):915-925

[21] LarkinsT L,NowellM,SinghS,SanfordG L.Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression.BMC Cancer, 2006, 6:181

[22] OkamotoA,ShirakawaT,BitoT,ShigemuraK,HamadaK,GotohA,Fujisawa M, Kawabata M. Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo.Urology,2008,71(1):156-160

[23] ZhaoH C,QinR,ChenX X,ShengX,WuJ F,WangD B,ChenG H.Microvessel density is a prognostic marker of human gastric cancer.World J Gastroenterol,2006,12(47):7598-7603

[24] SleemanJ P,CremersN.New concepts in breast cancer metastasis: tumor initiating cells and the microenvironment.Clin Exp Metastasis,2007,24(8):707-715

版权

2014 Higher Education Press and Springer-Verlag Berlin Heidelberg